Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Industry

3 Feb 2022

CEO Interview: Journey Colab

Our conversation with co-founder and CEO Jeeshan Chowdhury gave us insight into a company not only working on an interesting and important indication (mescaline for addiction) but with a social...

By Jason Najum

Finance

3 Feb 2022

New Psychedelic ETF Launches on the NASDAQ

Despite a tough half-year in the market, the launching of a new ETF on the prestigious NASDAQ exchange is positive news for the industry....

By Jason Najum

Don’t Miss

31 Jan 2022

News You Might Have Missed: Jan 31st, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news items to help you catch up and stay informed ....

By Jason Najum

Breaking News

25 Jan 2022

Breaking News: FDA Clears MindMed’s Phase 2b LSD Trial

FDA clearance leads to first commercial IND for LSD, enabling MinfdMed to start Phase 2b dose-optimization trial in early 2022...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

21 Jan 2022

Psychedelic Decriminalization Update

A look a recent decrim measures across the psychedelic space....

By Jason Najum

Industry

18 Jan 2022

Update on Revive Therapeutics Psilocybin Programs

Revive Therapeutics has just released an update of its psychedelic pipeline, so we thought it’d be a good time to check in and see what’s up....

By Jason Najum

Don’t Miss

17 Jan 2022

News You Might Have Missed: Jan 17th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic industry news to help you catch up and stay informed....

By Jason Najum

Finance

14 Jan 2022

Psychedelic Stocks to Watch in 2022

While 2022 hasn’t yet given us the market turnaround we had hoped for, the forthcoming 12 months will filled with clinical trial news and significant milestones....

By Jason Najum

Industry

12 Jan 2022

Field Trip’s FT-104 Clears Patent Approval Process

The Allowance is final major step in the patent process, with actual granting of the patent normally coming soon after....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.